Chemotherapy with G-CSF is used to mobilize peripheral stem cells in multiple myeloma (MM) patients, with plerixafor as a rescue strategy for poorly mobilizing patients. Preclinical studies suggested that the nonsteroidal anti-inflammatory drug meloxicam enhances the mobilization of CD34 + cells. In this single-center study, we evaluated whether adding meloxicam to chemotherapy/ G-CSF mobilization increases peripheral hematopoietic CD34 + cell levels and reduces the need of using plerixafor. We prospectively compared two consecutive cohorts of MM patients in first remission mobilized with G-CSF and nonmyelosuppressive chemotherapy with vinorelbine or gemcitabine. The second cohort additionally received oral meloxicam. The cohorts comprised 84 patients without meloxicam (− M) and 66 patients with meloxicam (+M). Meloxicam was well tolerated and associated with similar hematologic engraftment after transplantation and equal survival rates. However, the meloxicam group had higher CD34 + cell levels on day 8 of the mobilization procedure (53 200 versus 35 600 CD34 + cells/mL; P = 0.007), and fewer patients needed 41 collection day (+M: 6 (9%) patients versus − M: 16 (19%) patients; P = 0.04). This resulted in reduced plerixafor administrations (+M: 7 (11%) patients versus − M: 18 (21%) patients; P = 0.03) and less costs. Our data suggest that meloxicam enhances the mobilization of hematopoietic CD34 + blood cells in MM patients.
INTRODUCTION
Symptomatic multiple myeloma (MM) is a malignant plasma cell disorder characterized by the presence of a specific monoclonal Ig and related organ damages. 1, 2 Numerous studies have established a role for bortezomib-based triple-induction regimens followed by high-dose melphalan treatment with autologous stem cell transplantation (ASCT) as first-line treatment in clinically fit MM patients. [3] [4] [5] [6] Within this algorithm, either G-CSF alone or in combination with cyclophosphamide is commonly used for the mobilization of hematopoietic progenitor cells (PBSC) to the peripheral blood before ASCT in MM patients. [7] [8] [9] [10] Alternatively, Swiss transplant centers routinely apply a non-myelosuppressive mobilization regimen combining a single dose of vinorelbine together with G-CSF for reliable harvest of PBSCs, whereas patients with bortezomib associated neuropathy are mobilized with gemcitabine and G-CSF. [11] [12] [13] [14] [15] However, up to 20% of MM patients poorly mobilize PBSCs following either cytokine treatment alone or together with chemotherapy. 13, 16, 17 For such patients, the additional use of the CXCR4 antagonist plerixafor represents a rescue strategy to mobilize a sufficient number of hematopoietic CD34 + cells enabling these patients ultimately to proceed to ASCT. Although being clearly effective in such patients, administering plerixafor is associated with significant financial burden. Finally, the cytokinebased mobilization procedure can provoke relevant transient bone pain making adequate pain management challenging in some patients. 13, 18 Recent preclinical studies have elucidated the role of prostaglandin E 2 (PGE 2 ) on the homeostasis of the stem cell niche. [19] [20] [21] [22] [23] [24] [25] In particular, nonsteroidal anti-inflammatory drugs (NSAIDs) were identified to enhance the mobilization of PBSCs. 19 This effect was independent of the SDF-1/CXCR4 axis, and such transplants mobilized with NSAIDs provided safe long-term engraftment of hematopoietic cells in murine models. Furthermore, the increased number of PBSC in PGE 2 deficient mice was found to be caused by impaired EP4 receptor signaling, suggesting a regulatory role of PGE 2 for stem cell retention in the bone marrow niche mediated by the EP4 receptor. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] In these reports, the COX-1 and COX-2 inhibitor meloxicam was predominantly used mainly because of its favorable safety profile with regards to gastrointestinal discomfort and inhibition of platelet aggregation. 19 Based on these facts, we intended to evaluate the effect of oral meloxicam treatment in addition to the standard chemotherapy/ G-CSF stimulation in MM patients. We investigated whether meloxicam treatment increased the mobilization of peripheral hematopoietic CD34 + cells, reduced the need for plerixafor administration, and provided adequate pain control during the stimulation procedure.
MATERIALS AND METHODS

Patient Population
were studied between July 2012 and June 2016. All patients had given written informed consent, and this study was approved by the local ethics committee of Bern, Switzerland with the decision number #375/15. Consecutive MM patients were summarized into a group without meloxicam ( − M; from July 2012 until October 2014) comprising patients with standard mobilization procedure (chemotherapy and G-CSF), and a group of patients (+M; from November 2014 until June 2016) receiving meloxicam in addition to the otherwise identical mobilization procedure.
Mobilization treatment
MM patients in first remission considered fit for high-dose chemotherapy received non-myelosuppressive chemotherapy together with G-CSF for mobilization of peripheral autologous stem cells. A single application of IV vinorelbine (35 mg/m 2 ; in the absence of peripheral neuropathy) or gemcitabine (1250 mg/m 2 ; in patients with peripheral neuropathy) was used together with G-CSF (0.5 IE/kg body weight twice daily) started at day 4 after chemotherapy and continued until (and including) the day of stem cell collection, as previously described. [15] [16] [17] [18] [19] [20] In addition, patients in the second group (+M) received oral meloxicam (7.5 mg given twice daily) from day 4 until day 8, thus on days with G-CSF. Stem cell collection was triggered at the first day (usually day 8 or 9) of peripheral blood CD34 + cell levels exceeding 20 000/mL. At least 3 ×10 6 CD34 + cells/kg body weight (b.w.) were aimed to be collected for a single autograft, and two autografts were routinely planned for each patient. Whenever possible, we aimed for a single-day collection.
Plerixafor use
For patients not achieving a sufficient level of mobilized CD34 cells, the additional use of the stem cell releasing compound plerixafor was defined as follows: an absolute dose of 24 mg intravenously applied plerixafor was given at 08:00 AM on day 9 followed by stem cell collection (on day 9) if (A) hematopoietic CD34 + cells failed to rise above 10 000/mL on day 8, or (B) if hematopoietic CD34 + cells still remained between 10 000-20 000/mL on day 9. CD34 + levels were determined in all patients on day 8, and they were repeated on day 9 in all patients not finishing collection on day 8. 13 
Autologous transplantation
For high-dose treatment, patients above 70 years received a reduced single dose of melphalan (140 mg/m 2 ), whereas 200 mg/m 2 melphalan was given in patients ⩽ 70 years. All patients received weight-adapted G-CSF starting at day 6 after ASCT until neutrophils exceeded 0.5 G/L for 3 consecutive days.
Definitions
The primary objective of the study was to assess the need for additional administration of the stem cell releasing compound plerixafor. The primary endpoint was the binary variable indicating whether a patient did not receive plerixafor at all or received plerixafor at least once. Given our previous institutional experience, the expected proportion of patients receiving at least a single dose of plerixafor following the mobilization procedure without meloxicam and the collection strategy outlined above was 22%. 13 The study was considered to be promising if in the meloxicam cohort the number of patients needing plerixafor was ⩽ 50% with respect to the number of plerixafor treated patients in the − M control cohort (that is, a 50% decrease; effect size − 0.11). With a significance level of α = 0.2 and a power of 1−β = 0.8, at least 63 patients per treatment cohort were needed. Secondary end points were differences in engraftment, overall survival, progression-free survival, pain control and safety.
Statistical analysis
Continuous data were summarized with median, minimum and maximum values, P-values were calculated using Wilcoxon rank-sum tests. Categorical data were summarized with frequency and percentage and compared between groups using Fisher's exact tests. For the primary analysis, the proportion of patients receiving plerixafor was compared between the two groups using a one-sided t-test, with the null hypothesis that the proportion of patients with plerixafor administration was not lower in patients with meloxicam than in patients without. As a secondary analysis, a logistic linear regression model was calculated considering the plerixafor administration as a dependent variable, whereas independent variables were meloxicam administration, age at stem cell mobilization (continuous), remission status before mobilization (CR, VGPR and PR versus SD and PD), bone marrow infiltration (continuous), sex and ISS stage. Survival analyses were calculated using the method of Kaplan and Meier and compared using the log-rank test. P-values o0.05 were considered statistically significant.
RESULTS
Patients
We identified 150 patients with symptomatic MM who underwent stem cell mobilization in first remission between July 2012 and July 2016 at the University Hospital Bern, Switzerland after bortezomib-based induction treatment. A first group of 84 patients was mobilized with G-CSF and non-myelosuppressive chemotherapy with either 35 mg/m 2 vinorelbine (n = 36; in the absence of peripheral neuropathy) or 1250 mg/m 2 gemcitabine (n = 48; in patients with polyneuropathy). [15] [16] [17] [18] [19] [20] The full dosage was given to all patients. The subsequent group comprised 66 patients with additional meloxicam treatment, with 35 patients receiving vinorelbine and 31 patients receiving gemcitabine. All patients in this group received the full dosage of chemotherapy and meloxicam. The clinical characteristics at diagnosis of all patients are summarized in Table 1 , with no differences between the two groups.
Hematopoietic stem and progenitor cell collection from the peripheral blood The minimum number of hematopoietic CD34 + cells to proceed to transplantation was 3 × 10 6 /kg b.w. per transplant, and, consistently, stem cells for two transplants were planned to be collected. A total of 129 MM patients (86%) achieved the pre-defined collection goal with a single apheresis day procedure, whereas 21 patients (14%) needed 2 days. In the -M group, 20% of the patients (n = 16) needed two apheresis days whereas in the +M group only 8% of the patients (n = 5) needed two apheresis days (P = 0.06). Although not being significant these data suggest that additional meloxicam treatment reduced the proportion of MM patients needing 41 collection day by 450%.
In 96 patients (64%), PBSCs were collected as planned on day 8 of their mobilization procedure, whereas 54 patients (36%) started apheresis later or needed 41 collection day. In the -M group, the collection procedure could be accomplished on day 8 in 56% of the patients (n = 47) as compared with 74% in the +M group (n = 49; P = 0.03). These observations indicate that additional meloxicam treatment allowed for more precise planning of the stem cell collection.
CD34
+ hematopoietic cell mobilization and plerixafor use
We observed a significant difference in the number of circulating peripheral CD34 + cells at day 8 between the two groups: The median levels of CD34 + cells were 35 600/mL (1100-451 400) and 53 200/mL (2200-239 500) for patients without and with meloxicam administration (P = 0.007). No differences in white blood cell number and cellular composition were observed between the two groups (Supplementary Table 1 ). These data indicate that meloxicam administration increased PBSC mobilization after stimulation with chemotherapy and G-CSF in MM patients.
The primary objective of the study was to identify whether meloxicam use reduced the need for plerixafor in poorly mobilizing MM patients. Whereas 18 (21%) patients needed at least one additional plerixafor administration in the group without meloxicam, only 7 (11%) patients in the +M group needed plerixafor support (P = 0.03). One patient without meloxicam and two patients in the meloxicam group had two plerixafor administrations. The clinical characteristics of the patient groups without and with plerixafor are summarized in Supplementary In a multivariate analysis investigating the six parameters meloxicam use, age, remission status at mobilization, bone marrow infiltration at diagnosis, gender and ISS stage at diagnosis, none of these parameters turned out to be significant, with a P = 0.16 (95% CI 0.15-1.33) for meloxicam use (Table 2) . Also, there was no significant effect of meloxicam use after applying backward elimination (Table 2) 3) in the meloxicam group. The total median apheresis duration was not different between the two groups (328 min versus 306 min; P = 0.36), whereas the median total processed blood volume was 33 000 ml (8141-95 250) and 26 020 ml (9700-83 570) for patients without and with meloxicam administration (P = 0.02), suggesting that more blood volume needed to be processed in patients without meloxicam to ultimately achieve similar final collection yields.
Pain assessment
We evaluated the pain associated with the G-CSF and chemotherapy mobilization procedure. Only one patient was hospitalized for pain treatment (in the meloxicam group). There was no significant difference in pain levels between the two groups (data available in 68 -M patients and 62 +M patients). Bone pain grade 2 or 3 according to the CTCAE Version 4.0 were reported in 8% (n = 7) of -M patients and in 18% (n = 12) of +M patients (P = 0.09). These observations indicate that additional meloxicam administration was not sufficient to reduce the proportion of patients experiencing bone pain during the mobilization procedure.
Outcome after ASCT A total of 148 MM patients ultimately received melphalan conditioning as planned, whereas two patients refused highdose treatment (and preferred to receive it later at first relapse). We observed no differences between the two groups in the median duration of hospitalization (19 days in both groups) or until hematological recovery (median platelet recovery 14 days versus 13 days after ASCT; median neutrophil recovery 12 days after ASCT in both groups) (Supplementary Table 3) .
Before ASCT, the rates of patients in CR or VGPR after induction treatment were comparable between the two groups (Table 1) . Similarly, we observed no differences in the CR rate 100 days after ASCT (45% in the -M group versus 47% with meloxicam; P = 0.35). Finally, we observed no differences in the PFS (P = 0.53) between the two groups nor in the OS (P = 0.40; Figure 1 ). This suggests that meloxicam treatment would not affect clinical outcome after high-dose chemotherapy with autologous stem cell transplantation. 18 (22) 17 (26
17 (20) 14 (21) Light chain Kappa, n (%) 49 (61) Abbreviations: ASCT = autologous stem cell transplantation; BM = bone marrow; ISS = International Staging System; MM = multiple myeloma; PB = peripheral blood; PD = progressive disease; RVD = velcade, dexamethasone and revlimid; SD = stable disease; VCD = velcade, dexamthasone and cyclophosphamide; VD = velcade and dexamethasone; VGPR = very good partial remission. Clinical characteristics and univariate analysis of MM patients treated with or without meloxicam during hematopoietic stem and progenitor cell mobilization. a Calculated creatinine clearance (Cockroft-Formula) o 60 ml/min.
DISCUSSION
Preclinical studies in murine models have suggested that the use of the NSAID meloxicam enhances mobilization of hematopoietic stem and progenitor cells (PBSC) from the bone marrow niche to the peripheral blood. In this study, we investigated in MM patients whether meloxicam treatment in addition to the standard mobilization procedure with chemotherapy and cytokine stimulation increases mobilization of PBSC and reduces the need for additional plerixafor administration. In fact, we found that meloxicam treatment enhanced PBSC mobilization. We observed increased levels of circulating hematopoietic CD34 + cells on day 8 after start of mobilization allowing a more reliable planning of the collection procedure at day 8.
To the best of our knowledge this is the first study investigating the effects of meloxicam for hematopoietic stem cell mobilization in MM patients. We generally observed an excellent tolerance of this treatment since no grade 2-4 side effects were reported. In addition, safe engraftment with NSAID enhanced autografts was observed in all patients, and no differences in hematological recovery were noted between patients mobilized with or without meloxicam. Finally, similar survival rates were seen in both treatment groups. These data suggest that using meloxicam for stem cell mobilization in MM patients is generally well tolerated and safe.
Previous reports suggested that PGE 2 has a regulatory role in the homeostasis of the stem cell niche, and that this effect is mediated by the EP4 receptor. 19 This pathway is independent of the SDF-1/CXCR4 axis and, thus, is not affected by treatment of specific compounds such as plerixafor. 19 Furthermore, NSAID treatment blocks PGE 2 and thus, enhances mobilization of stem cells. 19 Also, NSAID can reduce SDF-1 and osteopontin, both leading to enhanced mobilization of hematopoietic stem and progenitor cells. 19, 25, 26 Our study in MM patients supports these preclinical data as we observed that the level of circulating CD34 + cells on day 8 of the mobilization procedure was markedly higher in patients treated with meloxicam. However, we cannot exclude the possibility that this is a meloxicam specific effect, and that other NSAID compounds might behave differently.
The improved peripheral CD34 + blood cell mobilization led to a reduced use of plerixafor in poorly mobilizing patients, which was associated with a meaningful reduction of costs. The need to apply plerixafor decreased from 21% (without meloxicam) to 11% (with meloxicam) in our cohort of MM patients allowing to save seven administrations of plerixafor in the meloxicam group of 66 patients. Considering the modest costs for meloxicam as compared with plerixafor, a significant reduction of costs was observed in the meloxicam group. In addition, meloxicam use was associated with fewer collection days. Finally, we observed that planning of the mobilization procedure was more reliable in the meloxicam group. Seventy-four percent of the meloxicam treated patients effectively started and finished their apheresis procedure on day 8 as planned compared with 56% in the group without meloxicam allowing more precise use of resources and staff.
Mobilization of autologous hematopoietic stem and progenitor cells with cytokines is notoriously associated with significant bone pain in some patients. We had reason to expect that the administration of the NSAID meloxicam might reduce pain levels in the meloxicam cohort. However, we observed no evidence of improved pain control in meloxicam treated patients. This may be partly caused by the fact that patients in the standard group consistently received paracetamol up to 4000 mg/day as prophylactic analgesic treatment, whereas this was not provided in the meloxicam group.
The obvious limitation of this study is the non-randomized, nonblinded and single-center design. In addition, and despite an otherwise homogenous mobilization procedure, this study compared two consecutive prospective cohorts introducing an inevitable time bias. Acknowledging these restrictions, our data indicate that meloxicam can be safely added to the mobilization procedure with non-myelosuppressive chemotherapy and G-CSF cytokine stimulation. Its use leads to significant enhancement of mobilized peripheral CD34 + blood cells, and is associated with a meaningful reduction of costs by lowering the use of the rescue compound plerixafor and by reducing the number and volume of the apheresis procedures needed. Although beyond the scope of this report, future studies will have to investigate various immunophenotypic compartments of the autografts obtained with versus without plerixafor, and with versus without meloxicam, respectively, in order to analyze how composition of autografts may be affected by previous treatment with meloxicam with and without plerixafor.
Our data suggest that using meloxicam can be considered a promising candidate supportive treatment within the routine mobilization algorithm in MM patients.
